Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder (复方青黄散) in Patients with Myelodysplastic Syndromes

  • Pan Zhao
  • Jun-bin Liang
  • Zhong-yang Deng
  • Ming-jing Wang
  • Jia-yue Qin
  • Chong-jian Chen
  • Xiao-mei Hu
Original Article



To investigate the relationship between gene mutations and response to Compound Qinghuang Powder (复方青黄散, CQHP) in patients with myelodysplastic syndrome (MDS).


Forty-three MDS patients were genotyped by ultra-deep targeted sequencing and the clinical data of patients were collected and the relationship between them was analyzed.


Up to 41.86% of patients harbored genet mutations, in most cases with more than one mutation. The most common mutations were in SF3B1, U2AF1, ASXL1, and DNMT3A. After treatment with CQHP, about 88.00% of patients no longer required blood transfusion, or needed half of prior transfusions.


CQHP is an effective treatment for patients with MDS, especially those with gene mutations in SF3B1, DNMT3A, U2AF1, and/or ASXL1.


myelodysplastic syndromes arsenic next-generation sequencing realgar 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Garcia-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015;90:831–841.CrossRefPubMedGoogle Scholar
  2. 2.
    Papaemmanuil E, Gerstung M, Malcovati L. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013;122:3616–3627.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Haferlach T, Nagata Y, Grossmann V. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28:241–247.CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang L, Padron E, Lancet J. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res 2015;39:6–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Smith AE, Mohamedali AM, Kulasekararaj A. Next generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010;116:3923–3932.CrossRefPubMedGoogle Scholar
  6. 6.
    Hu XM, Liu F, Ma R. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. Chin J Integr Med 2010;16:368–477.CrossRefPubMedGoogle Scholar
  7. 7.
    Ma JL, Qu WW, Hu XM. Arsenic preparation for application in the treatment of myelodysplastic syndrome. Chin J Clin (Electr ed, Chin) 2012;6:149–150.Google Scholar
  8. 8.
    Hu XM, Wang HZ, Mao C, Liu C, Li L, Zheng CM, et al. Clinical significance of trisomy 8 and monosomy 7/7q deletion in myelodysplastic syndrome. J Clin Hematol (Chin) 2006;19:340–343.Google Scholar
  9. 9.
    Hu XM, Ma JL, Ma R. Selectivity of treatment to clone category in patients with myelodysplastic syndromes. J Leuk Lymph (Chin) 2011;20:759–761.Google Scholar
  10. 10.
    Ma JL, Qu WW, Hu XM. Correlationship of clonal selection of treatment with arsenious compound formula Qinghuang Powder with in vivo effects of arsenic in patients with myelodysplastic syndrome. Chin J Inf Tradit Chin Med (Chin) 2013;20:5–8.Google Scholar
  11. 11.
    Sun SZ, Ma R, Hu XM, Yang XH, Xu YG, Wang HG, et al. Karyotype and DNA-methylation responses in myelodysplastic syndromes following treatment with traditional Chinese formula containing arsenic. Evid Based Complement Alternat Med 2012;2012:969476.Google Scholar
  12. 12.
    Vanlet P, Horny HP, Bennet JM, Christa F, Ulrich G, Peter G, et al. Definitions and standards in the diagnosis and treatment of myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727–736.CrossRefGoogle Scholar
  13. 13.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008:88–93.Google Scholar
  14. 14.
    Shaffer LG, Tommerup N, eds. An international system for human cytogenetic nomenclature. Basel: S. Karger Publishers; 2005.Google Scholar
  15. 15.
    Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofi brosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497–1503.CrossRefPubMedGoogle Scholar
  16. 16.
    Zheng XY, ed. Guidelines for the clinical research of traditional Chinese medicine (Trial). Beijing: China Medical Science and Technology Press; 2002:19–20.Google Scholar
  17. 17.
    Hu XM, Ma R, Xu YG, GUO XQ, Xu S, Liu F, et al. Application of Qinghuang Powder in treating hematologic malignancies. Int J Tradit Chin Med (Chin) 2011;33:568–570.Google Scholar
  18. 18.
    Xu S, Ma R, Hu XM. Clinical observation on Qinghuang Powder for treatment of 31 cases of myelodysplastic syndrome. J Tradit Chin Med (Chin) 2006;47:514–516.Google Scholar
  19. 19.
    Xu S, Hu XM, Xu YG, Yang XH, Wang HZ, Liu F, et al. Effect of treatment for myelodysplastic syndrome by Qinghuang Powder combined with Chinese herbs for reinforcing Shen and strenghening Pi. Chin J Integr Chin West Med (Chin) 2008;28:216–219.Google Scholar
  20. 20.
    Liu F, Guo XQ, Hu XM, Xu YG, Wang HZ, Yang XH, et al. Effect of Qinghuang Powder in treating 36 patients with myelodysplastic syndrome. J Tradit Chin Med (Chin) 2011;52:241–242.Google Scholar
  21. 21.
    Xu S, Ma R, Hu XM, Xu YG, Yang XH, Wang HZ, et al. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder. Chin J Integr Med 2011;17:834–839.CrossRefPubMedGoogle Scholar
  22. 22.
    Wang Y, Fang S, Song MM, Hu XM. Safety of compound Qinghuang powder in patients with myelodysplastic syndromes. Int J Tradit Chin Med (Chin) 2014;37:1074–1077.Google Scholar
  23. 23.
    Wang Y, Fang S, Deng ZY, Song MM, Ma JL, Yang XP, et al. Compound Qinghuang Powder in the treatment of patients with myelodysplastic syndromes. Int J Tradit Chin Med (Chin) 2015;37:1091–1095.Google Scholar
  24. 24.
    Wang FR, Lou YQ, Lu DP. Study on clinical pharmacokinetics of oral Tetraarsenic tetrasulfide. Chin J Hematol (Chin) 2005;26:44–46.Google Scholar
  25. 25.
    Ni JH, Chen GQ, Shen ZX, Li XS, Liu HW, Huang YT, et al. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin J Hematol (Chin) 1997;18:250–253.Google Scholar
  26. 26.
    Hu XM, Tanaka S, Onda K, Yuan B, Toyoda H, Ma R, et al. Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7. Chin J Integr Med 2014;20: 387–393.CrossRefPubMedGoogle Scholar
  27. 27.
    Hu XM, Yuan B, Tanaka S, Song MM, Onda K, Tohyama K, et al. Arsenic disulfi de-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines. Hematology 2014;19:352–360.CrossRefPubMedGoogle Scholar
  28. 28.
    Hu XM, Yuan B, Song MM, Onda K, Tanaka S, Toyoda H, et al. Dose-dependent biphasic effects of arsenic disulfi de on differentiation and apoptosis of HL-60 cells. Curr Topics Pharmacol (Chin) 2014;17:13–25.Google Scholar
  29. 29.
    Hu XM, Yuan B, Tanaka S, Zhou QB, Onda K, Toyoda H, et al. Involvement of oxidative stress associated with glutathione depletion and p38 MAPK activation in arsenic disulfide-induced differentiation in HL-60 cells. Leuk Lymphom 2014;55:392–404.CrossRefGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2018

Authors and Affiliations

  • Pan Zhao
    • 1
  • Jun-bin Liang
    • 2
  • Zhong-yang Deng
    • 1
  • Ming-jing Wang
    • 1
  • Jia-yue Qin
    • 2
  • Chong-jian Chen
    • 2
  • Xiao-mei Hu
    • 1
  1. 1.Department of Hematology, Xiyuan HospitalChina Academy of Chinese Medical SciencesBeijingChina
  2. 2.Annoroad Gene Technology Co. Ltd.BeijingChina

Personalised recommendations